- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00625131
Nicotine Patch Pretreatment for Smoking Cessation in PTSD
Nicotine Patch Pre-treatment for Smoking Cessation in PTSD
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Smokers with PTSD will be randomly assigned to 1 of 2 pre-cessation patch therapy conditions (active patch versus placebo patch) for three weeks before a target quit-smoking date. All participants to will receive bupropion beginning 1 week prior to their quit day, given that they are medically eligible to be prescribed bupropion. All participants will receive a two session brief cognitive-behavioral therapy (CBT) session and will begin standard nicotine replacement therapy (NRT) on their quit day. PTSD symptoms, mood, and smoking craving will be carefully evaluated throughout the study using electronic diary assessments on personal digital assistants (PDA). Specifically, participants will carefully monitor their symptoms, mood, craving, and use of cigarettes using electronic diaries for one week prior to the pre-cessation period, during the 3-week pre-cessation treatment period, and 6 weeks post quit date. Since no previous study has examined factors associated with smoking abstinence following treatment among PTSD smokers10, predictors of treatment response will be examined. The study is designed to address the following items:
Specific Aim 1: To evaluate whether supplemental nicotine administration (i.e., pre-cessation treatment with nicotine patch and bupropion) will result in improved quit rates among smokers with PTSD.
Hypothesis 1.1 Supplemental nicotine administration during the pre-cessation period will result in improved quit rates in the first quit week over the placebo patch condition.
Specific Aim 2: To utilize electronic diary assessment of PTSD symptoms, mood, smoking craving, and smoking during baseline, pretreatment, and quit periods to evaluate potential mechanisms of how pretreatment with the nicotine patch may increase abstinence rates.
Hypothesis 2.1 Supplemental nicotine administration will decrease craving for cigarettes during the 2 week pretreatment period as compared to the placebo patch condition.
Hypothesis 2.2 Supplemental nicotine administration will decrease the perceived improvement in mood and PTSD symptoms associated with smoking behavior, i.e., symptom relief from ad lib smoking a cigarette will be reduced during supplemental nicotine administration as compared to the placebo patch condition.
Specific Aim 3: To investigate potential predictors of smoking abstinence and relapse associated with individual differences in affective style including anxiety sensitivity, measures of distress tolerance, and self-efficacy.
Hypothesis 3.1 Increased anxiety sensitivity will be predictive of shorter abstinence from smoking.
Hypothesis 3.2 Decreased distress tolerance will be predictive of shorter abstinence.
Hypothesis 3.3 Lower self-efficacy for smoking abstinence will be predictive of shorter abstinence.
Hypothesis 3.4 Increased PTSD symptoms severity and negative affect following the quit date will be associated with shorter abstinence.
Studietyp
Inskrivning (Faktisk)
Fas
- Tidig fas 1
Kontakter och platser
Studieorter
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27705
- VA Medical Center, Durham
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Smokers who smoke 10 or more cigarettes per day in the past year;
- 18-80 years old;
- English speakers;
- medically stable;
- stable on current medication regimen
Exclusion Criteria:
- Pregnant women excluded;
- participants with organic mental disorder, schizophrenia, bipolar disorder, lifetime but not current PTSD, current substance abuse or dependence;
- medical conditions contraindicated with nicotine replacement therapy;
- use other forms of nicotine (cigars, nicotine gum, etc.)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Active Nicotine Patch Group
Transdermal nicotine patch
|
Delivered through transdermal nicotine patch
Manualized protocol for CBT in smoking cessation
Andra namn:
Antidepressant
Andra namn:
|
Placebo-jämförare: Placebo Patch Group
Transdermal placebo patch
|
Manualized protocol for CBT in smoking cessation
Andra namn:
Antidepressant
Andra namn:
Pre-treatment placebo transdermal patch
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Smoking Abstinence, Self-reported
Tidsram: Week prior to Session 12 at 6 weeks post-treatment
|
Number of participants by group reporting 1 week of self-reported abstinence in the week prior to Session 12 at six weeks post-treatment
|
Week prior to Session 12 at 6 weeks post-treatment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Carbon Monoxide Monitoring
Tidsram: Session 12 (6 weeks post-treatment)
|
Number of participants whose carbon monoxide (CO) measurement indicated abstinence at Session 12 (6 weeks post-treatment)
|
Session 12 (6 weeks post-treatment)
|
Smoking Craving
Tidsram: Daily between visits 2-12
|
Mean smoking craving score (as measured during daily ecological momentary, or diary, assessments) for participants by group during the two week period of placebo/active pre-treatment.
This is the main period of interest, as it was hypothesized that use of active nicotine patch would reduce smoking cravings during the pre-quit period.
The craving score is based on a single diary item "Please rate your desire to smoke right now" with a Likert scale score ranging from 1 (none) to 5 (severe).
Higher craving is "worse," as lower craving is presumed to reflect decreased risk of smoking lapse or relapse.
|
Daily between visits 2-12
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Jean C. Beckham, PhD, VA Medical Center, Durham
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Mentala störningar
- Kemiskt inducerade störningar
- Patologiska processer
- Substansrelaterade störningar
- Trauma och stressorrelaterade störningar
- Sjukdom
- Stressstörningar, traumatiska
- Stresssyndrom, posttraumatisk
- Störning av tobaksbruk
- Läkemedels fysiologiska effekter
- Neurotransmittormedel
- Molekylära mekanismer för farmakologisk verkan
- Autonoma agenter
- Agenter från det perifera nervsystemet
- Kolinerga medel
- Enzyminhibitorer
- Psykotropa droger
- Neurotransmittorupptagshämmare
- Membrantransportmodulatorer
- Antidepressiva medel
- Dopaminmedel
- Cytokrom P-450 enzymhämmare
- Ganglionstimulerande medel
- Nikotinagonister
- Kolinerga agonister
- Antidepressiva medel, andra generationen
- Cytokrom P-450 CYP2D6-hämmare
- Dopaminupptagshämmare
- Nikotin
- Bupropion
Andra studie-ID-nummer
- NEUA-007-07F
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Störning av tobaksbruk
-
University of KonstanzAfrica Mental Health FoundationAvslutad
-
Eunice Kennedy Shriver National Institute of Child...AvslutadEnvironmental Tobacco Smoke (ETS)Förenta staterna
-
University of KonstanzAfrica Mental Health FoundationAvslutadPosttraumatisk stressyndrom | Khat Use DisorderKenya